ZytoVision FISH probe for ROS1 translocations
Products are for professional/laboratory use only.
For patients with advanced lung cancer, the expected median survival is approximately one year however treatment with targeted tyrosine kinase inhibitor (TKI) therapy can improve outcomes for patients who have certain molecular alterations that can be identified by molecular testing1.